Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call
April 28 2022 - 6:30AM
Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ:
VVOS), a medical technology company focused on developing and
commercializing a suite of innovative diagnostic and treatment
modalities for patients with dentofacial abnormalities and/or mild
to moderate obstructive sleep apnea (OSA) and snoring in adults,
today announced that it plans to release financial results for the
first quarter ended March 31, 2022 after market close on Monday,
May 16, 2022. The Company will conduct a conference call the same
day at 5:00 pm (Eastern Time) to review the results as well as
provide an overview of the Company’s recent milestones and growth
strategy.
To access the conference call, please dial (888)
256-1007, or for international callers, (720) 543-0214. A replay
will be available shortly after the call and can be accessed by
dialing (844) 512-2921, or for international callers, (412)
317-6671. The passcode for the live call and the replay is 5800759.
The replay will be available until May 30, 2022.
A live webcast of the conference call can be
accessed on Vivos’ website at https://vivos.com/investor-relations.
An online archive of the webcast will be available on the Company’s
website for 30 days following the call.
About Vivos Therapeutics,
Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a
medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from dentofacial abnormalities and/or mild to
moderate sleep apnea (OSA) and snoring in adults. The Vivos Method
represents the first clinically effective non-surgical,
non-invasive, non-pharmaceutical and cost-effective solution and
has proven effective in approximately 25,000 patients treated
worldwide by more than 1,450 trained dentists.
Combining proprietary technologies and
treatments that alter the size, shape and position of the tissues
that comprise a patient’s upper airway, The Vivos Method opens
airway space and may significantly reduce symptoms and conditions
associated with mild to moderate OSA, such as lowering Apnea
Hypopnea Index scores. Vivos also markets and distributes
SleepImage diagnostic technology under its VivoScore program for
Home Sleep Testing in adults and children. The Vivos Integrated
Practice (VIP) program offers dentists training and other
value-added services in connection with using The Vivos Method.
For more information, visit www.vivos.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release, the
conference call referred to herein, and statements of the Company’s
management made in connection therewith contain “forward-looking
statements” (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended) concerning future events, particularly with
respect to the public offering described herein. Words such as
“aim”, “may”, “could”, “should”, “expects”, “projects,” “intends”,
“plans”, “believes”, “predicts”, “anticipates”, “hopes”,
“estimates” and variations of such words and similar expressions
are intended to identify forward-looking statements. These
statements involve known and unknown risks and are based upon
several assumptions and estimates, which are inherently subject to
significant uncertainties and contingencies, many of which are
beyond Vivos’ control. Actual results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, the risk factors described in
Vivos’ filings with the Securities and Exchange Commission (“SEC”).
Vivos’ filings can be obtained free of charge on the SEC's website
at www.sec.gov. Except to the extent required by law, Vivos
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Vivos' expectations with
respect thereto or any change in events, conditions, or
circumstances on which any statement is based.
Vivos Investor Relations
Contact:Julie GannonInvestor Relations Officer(303)
859-3847jgannon@vivoslife.com
Vivos Media Relations
Contact:Francesca DeMauro / Jenny RoblesKCSA Strategic
Communications(917) 880-9771 / (212) 896-1231fdemauro@kcsa.com /
jrobles@kcsa.com
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Apr 2024 to May 2024
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From May 2023 to May 2024